Telomir Pharmaceuticals (TELO) announced that the U.S. Food and Drug Administration, FDA, has cleared the Company’s Investigational New Drug, IND, application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer, TNBC.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELO:
- Telomir Pharmaceuticals Completes TELI Acquisition, Expands Telomir-1 Rights
- Telomir Pharmaceuticals completes acquisition of TELI Pharmaceuticals
- Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance
- Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in TNBC
- Telomir Shareholders Approve Equity Plan and Bylaw Changes